Table of evidence of studies of PsA
| Study | Biologic | Design | Duration | N | Q | LE | Age* | DD* | Women (%) | HLAB27+(%) | Prior biologics (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antoni et al4 | IFX | RCT | 24 | 100 | 0.67 | 3 | 47.1 | 8.4 | 29.0 | NA | 0.0 |
| Chandran et al61 | NA | OP | 11 | 40 | 0.66 | 2 | 44.0 | 12.0 | 30.0 | NA | NA |
| Chimenti et al62 | ADA, ETN | RCT | 22 | 55 | 0.89 | 3 | 48.7 | 6.5 | 51.0 | NA | 0.0 |
| di Minno et al63 | IFX, ETN, ADA | OP | 96 | 270 | 0.88 | 2 | 51.7 | 9.2 | 45.9 | NA | 0.0 |
| Eder et al64 | IFX, ETN, ADA, GOL | OP | 48 | 95 | 0.75 | 2 | 45.7 | 11.8 | 67.9 | NA | 9.6 |
| Gladman et al66 | ADA | RCT | 48 | 285 | 0.61 | 3 | NA | NA | NA | NA | NA |
| Gladman et al65 | ADA | RCT | 24 | 144 | 0.90 | 3 | 47.8 | 9.9 | 43.7 | NA | 0.0 |
| Glintborg et al67 | IFX, ADA, ETN | OR | 24 | 746 | 0.76 | 4 | 47.0† | 5.0† | 52.0 | NA | 0.0 |
| Gratacos et al68 | IFX | OP | 38 | 69 | 0.85 | 2 | 42.5 | 8.0 | 60.8 | NA | 0.0 |
| Iannone et al69 | IFX, ETN, ADA | OR | NA | 135 | 0.86 | 4 | 53.2‡ | 10.0‡ | 49.6 | NA | 0.0 |
| Iervolino et al70 | IFX, ETN, ADA | OP | 12 | 136 | 0.90 | 2 | 45.6 | 5.2 | 58.4 | NA | 0.0 |
| Karanikolas et al71 | ADA | RCT | 48 | 113 | 0.88 | 3 | 46.3 | 7.9 | 55.7 | 23.0 | 0.0 |
| Kavanaugh et al72 | IFX | RCT | 54 | 100 | 0.67 | 3 | 47.1 | 8.4 | 29.0 | NA | 0.0 |
| Kavanaugh et al73 | GOL | RCT | 24 | 292 | 0.65 | 3 | 46.9 | 7.4 | 40.0 | NA | 0.0 |
| Kristensen et al74 | IFX, ETN, ADA | OP | 48 | 261 | 0.70 | 2 | 47.3 | 8.4 | 50.5 | NA | 0.0 |
| Marotta et al75 | ADA | OP | 12 | 24 | 0.53 | 3 | NA | NA | NA | NA | NA |
| Mease et al76 | ADA | RCT | 12 | 151 | 0.68 | 3 | 48.6 | 9.8 | 43.7 | NA | 0.0 |
| Morales-Lara et al43 | IFX | OP | 48 | 16 | 0.50 | 2 | NA | NA | NA | NA | NA |
| Ramirez et al77 | IFX, ETN, ADA | OP | 24 | 103 | 0.78 | 2 | 49.0† | 12.0† | 47.6 | 23.3 | 0.0 |
| Saber et al78 | IFX, ETN, ADA | OP | 12 | 152 | 0.73 | 2 | 45.0† | 8.0† | 52.3 | NA | 0.0 |
| Spadaro et al79 | ETN | OP | NA | 82 | 0.56 | 3 | 51.8 | 9.1 | 42.6 | NA | NA |
| Van den Bosch et al80 | ADA | OP | 12 | 442 | 0.76 | 2 | 47.8 | 10.6 | 50.0 | 23.3 | 14.9 |
| Wagner et al81 | GOL | RCT | 14 | 74 | 0.80 | 3 | 48.5 | NA | 36.0 | NA | 0.0 |
*Data are expressed in mean (years).
†Data are expressed in medians.
‡Data were calculated in the review.
ADA, adalimumab; DD, disease duration; ETN, etanercept; GOL, golimumab; IFX, infliximab; LE, level of evidence; N, number of patients; NA, not available; OP, observational prospective; OR, observational retrospective; Q, quality; RCT, randomised clinical trial.